Today, Boston Scientific shared its financial results for the third quarter of 2026.
Overall, we generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5% on a reported and organic basis1 compared to the prior year period.
We also achieved net sales growth in each of our reportable segments, with 0.7% organic growth1 in MedSurg and 1.9% organic growth1 in Cardiovascular compared to the prior year period.
"This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," says Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation."
Additional Q3 highlights:
- We received U.S. Food and Drug Administration (FDA) 510(k) clearance for two technologies within the StoneSmart™ Solutions ecosystem, including the Navigator™ Flex Ureteral Access Sheath Set, designed to enable the use of suction to remove kidney stone debris, and the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with temperature sensing, designed to display real-time fluid temperature alongside ureteroscopy video for procedural monitoring.
- We received U.S. FDA 510(k) clearance for an expanded size offering of the SEISMIQ™ Intravascular Lithotripsy Peripheral Catheter to treat patients with severely calcified peripheral artery disease both above and below the knee.
- The American Medical Association assigned Category I Current Procedural Terminology (CPT®) codes for renal denervation devices, such as the investigational TIVUS™ Renal Denervation System, and implantable tibial nerve stimulation (ITNS) devices, including the eCoin® ITNS System, effective January 2028.
- We entered into a strategic collaboration with Heartflow, Inc. (Nasdaq: HTFL) to advance AI-powered, computed tomography (CT)-guided planning for percutaneous coronary intervention (PCI) procedures and explore integration of Heartflow's PCI Navigator pre-procedural planning tool and the AVVIGO™+ Multi-Modality Guidance System.
For the full Boston Scientific earnings announcement and more business highlights from the third quarter of 2026, see the press release.
1Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the fourth quarter and full year 2026; our financial performance; impacts of the August 2026 cybersecurity incident; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our prior and new restructuring programs; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A. Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached below.
Net sales for the quarter by business:
